Compare Google Inc (GOOG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Recursion Pharmaceuticals Inc — how do they compare? Google Inc trades at $347.86 (market cap $4.24T), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Google Inc is far larger — about 1981.3× Recursion Pharmaceuticals Inc's market cap, and Google Inc pays a 0.26% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| GOOG | RXRX | |
|---|---|---|
Market Cap | $4.24T | $2.14B |
Volume | 13,937,902 | 30,789,535 |
Sector | Media | Health |
52-Week High | $399.06 | $6.79 |
52-Week Low | $237.49 | $2.84 |
Typical Hold Time | 137 Days | 23 Days |
Enterprise Value | $4.13T | $1.66B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $344.86, down 0.72% on the day, with strong technical support at $342 and resistance at $348. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $435.24 consensus price target, representing 26% upside potential.
The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors should monitor elevated capital expenditures and potential regulatory risks. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, with upcoming Q3 earnings on October 31, 2026, serving as the next key catalyst.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
